What patent protections did Novartis hold for alpelisib that relate to a “WO 2009” filing?
The alpelisib drug (Piqray) is tied to multiple patent families covering synthesis (process) and broader uses. A request for “alpelisib synthesis patent WO 2009 Novartis” typically refers to a PCT publication (WO) filed around 2009 that describes manufacturing or related synthetic routes.
However, the specific WO number (e.g., WO 2009xxxxx) and the exact assignee name (Novartis vs. a Novartis affiliate) are needed to identify the correct synthesis patent document and confirm its scope.
If you share the WO publication number (even partially) or a link/citation you saw, I can pin down:
- the exact patent publication (WO 2009…),
- whether it is a process/synthesis claim set or a compound/use claim set,
- and which Novartis entity is listed as applicant/assignee.
How do “WO 2009” synthesis patents for alpelisib usually map to Piqray’s commercial IP?
For small-molecule oncology drugs like alpelisib, synthesis/process patents filed years before approval are often used to extend control over:
- specific intermediates,
- specific reaction conditions,
- purification steps,
- or alternative routes that support later manufacturing scale-up.
Those process claims can exist alongside other patent types in the same family, such as:
- composition-of-matter (the core molecule),
- specific medical uses (indications),
- or crystalline form / solid-state properties.
A “WO 2009” synthesis publication generally belongs to the earlier-generation portion of these protection sets, but whether it remains enforceable depends on:
- the national phase filings,
- priority dates,
- term adjustments,
- and any later amendments or invalidity outcomes.
Where can you verify the exact alpelisib patent family and WO 2009 publication details?
DrugPatentWatch.com is a practical starting point to identify the relevant alpelisib patent families, including early WO publications and links to the underlying documents. [1]
If you want, paste the relevant DrugPatentWatch page (or the WO number shown there), and I can help interpret what the “synthesis/process” claims cover based on the document.
What I need from you to answer precisely
Please provide one of the following:
- The full WO publication number (format like WO 2009xxxxxx), or
- A link to the patent listing you mean, or
- The exact title/claim snippet you saw, or
- The DrugPatentWatch page URL you are referencing.
Once I have that, I can extract and summarize the synthesis-related scope tied to the Novartis WO 2009 alpelisib patent.
Sources:
[1] https://www.drugpatentwatch.com